Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC: Tweetorial #1 Evaluation (ID: i805-4)

1.How many years have you been in practice?(Required.)
2.How many patients with ES-SCLC do you manage per week?(Required.)
3.Please select the option that best describes your practice setting.(Required.)
4.After participating in this activity, how confident are you in the management of patients with ES-SCLC in your practice? (Required.)
5.How committed are you to making changes in your practice based on your participation in this activity?(Required.)
6.Which of the following best describes the impact of this activity on your performance?(Required.)
7.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)
8.What barriers do you see to making changes in your practice? Please select all that apply.  (Required.)
9.Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Compare efficacy and safety data for new and emerging treatments for second-line extensive-stage-SCLC (ES-SCLC), as well for immunotherapies approved in subsequent lines
Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy
10.Please rate your level of agreement by checking the appropriate rating.

Narjust Duma, MD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Avoided Commercial Bias
11.Please rate your level of agreement by checking the appropriate rating.

Jacob M. Sands, MD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Avoided Commercial Bias
12.The content presented:  (Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Addressed my most pressing questions
Promoted improvements or quality in health care
Was scientifically rigorous and evidence based
Avoided commercial bias or influence
13.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
14.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for ES-SCLC:
15.If you indicated that you perceived commercial bias or influence, please describe:
Privacy & Cookie Notice